Ann: Half Yearly Report and Accounts, page-2

Below extract from half year report. I might be wrong but it is my impression it sounds the opposite to what has been flagged for several months by Diamond and with a big disappointment also by Ms Gittleson.

Quote
“Partnering and licensing
Due to the significant costs in drug discovery and development it is common for biotechnology companies to partner with larger biotechnology or pharmaceutical companies to help progress drug development. While the Company has previously entered into such licensing agreements with pharmaceutical partners, there is no guarantee that the Company will be able to maintain such partnerships or license its products in the future. There is also no guarantee that the Company will receive back all the data generated by or related intellectual property from its licensing partners. In the event that the Company does license or partner the drugs in its pipeline, there is no assurance as to the attractiveness of the commercial terms nor any guarantee that the agreements will generate a material commercial return for the Company”
Unquote.